As the rate-limiting step to androgen production, some inhibitors against the 3βHSD1 protein product for prostate cancer have been developed, and it has been found that the HSD3B1 CC genotype predicts worse outcomes in PC patients that receive hormone therapies [4,7,8]. Here, HSD3B1 is linked to pachyonychia congenita.